• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

In Vivo Imaging Enables Researchers To View Biological Processes At The Molecular Level

Posted on: Tuesday, 21 November 2006, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c45678) has announced the addition of "From Structure to Function: In Vivo Molecular Imaging" to their offering.

Decision Resources provides the following information:

Introduction

In vivo imaging enables researchers to view biological processes at the molecular level. In vivo molecular imaging techniques have important implications for drug discovery and development because they aid in validating drug targets and in studying the biodistribution, target binding, clinical effects, and toxicity of drug candidates.

Get the Answers You Need to Shape Your Strategy

The development of in vivo molecular imaging techniques has important implications for drug discovery and development. How will pharmaceutical companies use this valuable information to accelerate their drug development process?

Which imaging companies are the major players in this field?

The FDA has introduced a new exploratory investigational new drug (eIND) mechanism that encourages companies to use imaging techniques during early- stage microdosing studies. How can pharmaceutical companies best capitalize on this new mechanism? Which imaging technologies are likely to see increased use as the result of eIND?

The high cost of in vivo molecular imaging poses a significant barrier to its widespread adoption.

Will pharmaceutical and biotech companies decide to invest in these technologies despite the cost or will they seek other options?

The development of combined PET- MRI instrumentation will be a major breakthrough. How close to market are these powerful new tools? What new benefits will they offer?

Scope

Factors fueling the molecular imaging market: trend toward systems biology and personalized medicine, FDA Critical Path initiative, and eINDs.

In vivo imaging technologies: computed tomography (CT), positron emission tomography (PET), single photon emission CT (SPECT), magnetic resonance imaging (MRI), functional MRI, optical imaging, and the use of model organisms.

Imaging initiatives: a review of important new imaging initiatives related to biomarkers, Alzheimer's disease, lung cancer, and osteoarthritis.

Applications of imaging to key therapeutic areas: a discussion of applications in cancer, the brain, and central nervous system disorders Corporate profiles: features on key players in this growing field. Outlook for molecular imaging: our take on how the role of molecular imaging in drug development will evolve over the next several years.

Companies Mentioned:

Affi body

Agfa HealthCare

Alerion Biomedical

Amersham

ART Advanced Research Technologies

Biospace Med

Bristol-Myers Squibb

Bruker Biospin

Caliper Life Sciences

Cardinal Health

CTI Molecular Imaging

Eastman Kodak Health Group

Eisai

Elan

Epix Pharmaceuticals

Fujifi lm Medical Systems USA

Gamma Medica-Ideas

GE Healthcare

General Electric

GlaxoSmithKline

Hamamatsu

iCAD

Insight NeuroImaging Systems

Invitrogen

Ixico

Johnson & Johnson

Kereos

Kodak

Li-Cor Biosystems

Eli Lilly

MDS Nordion

Merck

MIR Preclinical Services

Molecular Insight Pharmaceuticals

Novartis

Pfi zer

Philips Medical Systems

Regional Nuclear Pharmaceuticals

Riverain

Roche

SA Instruments

Siemens Medical Solutions

Stentor

Varian Instruments

VisEn Medical

Wyeth

Xenogen

Zecotek

Zygogen

For more information visit http://www.researchandmarkets.com/reports/c45678

Source: Decision Resources

Source: Business Wire

More News in this Category